Business Wire

ICCPP GROUP Will Represent Global Premier E-cigarette Companies to Participate in GFN2023 to Explore A Better Future for Tobacco Harm Reduction with Industry Experts

Share

On behalf of international excellent e-cigarette companies, ICCPP Group, the parent company of VOOPOO, DRAGBAR and Bdranded ODM+, will be invited to participate in the 2023 Global Forum on Nicotine (GFN2023) from 21st of Jun. to 24th of Jun.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230621311952/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

(Graphic: Business Wire)

GFN2023 is themed around “Tobacco Harm Reduction (THR) - The Next Decade”, inviting nearly 500 global tobacco experts, WHO representatives, industry leaders, e-cigarette consumers, tobacco organization representatives, health research scientists and media journalists to gather in Warsaw to provide global technical and governance solutions on the important topic of THR, and to jointly explore and promote the future development and expansion of THR direction.

ICCPP and GFN: Like-minded, Different Paths

ICCPP Group, is a globalization and full industry chain layout electronic atomization ecological group, integrating electronic atomization technology research and development, product design, intelligent manufacturing, brand operation and supply chain management. It has become a key influencer in electronic atomization industry with three major businesses that deeply run though B-sides and C-sides in less than a decade. For example, VOOPOO, the global well-known open system e-cigarette brand, DRAGBAR, the quickly rising disposable brand star, and Branded ODM+, the first branded e-cigarette business aiming at providing a user-centered, comprehensive and precise empowerment for B-size customers. At present, ICCPP’s products and solutions are used and enjoyed by more than 36 million consumers in over 70 countries around the world.

Although this is the first time for ICCPP Group to participate in GFN2023 and to expose as a new face at the global summit specializing in THR, there is a long history of connection between what ICCPP and GFN has been doing. ICCPP not only has the same long history as GFN, founded in 2014, but also shares the same operation philosophy: to make people's lives happier and better through their self own efforts. The difference is that GFN has chosen to provide a fair stage for dialogue and exchange of opinions among different nicotine industry stakeholders, while ICCPP, playing the role of athlete, is focusing on research and application of electronic atomization technology, and bringing more abundant electronic cigarette substitutes for adult smokers through its continuous innovation in technology and products. Even though they choose different paths, all roads lead to Rome.

ICCPP’s New tobacco Research: Pressure and Motivation

In addition, years of scientific research and user studies have made ICCPP to realize that the real challenges on the nicotine market are enormous. On one hand, there is a relative lack of empirical evidence on the harm reduction effects of new tobacco products, and the current scientific research results cannot clarify the clear effect of new tobacco products on the human body, or at least there is no way to make the government and the public dispel the concerns of the harmfulness of using new tobacco products. On the other hand, the public's awareness of the harm-reducing effects of new tobacco products is inadequate, and many people equate new tobacco products, such as vapes and HNB products with traditional tobacco, and talk about them in the same way. Research institutions, social organizations, industry teams, and industry stakeholders have very limited publicity about the harm-reducing research and effects of new tobacco products. All of this has caused tremendous pressure on new tobacco harm reduction research of ICCPP, but pressure often means motivation.

As one of the few invited representatives of global e-cigarette companies, ICCPP Group, in a responsible corporate sentiment, is very willing to share its latest research results on nicotine, THR and environmental protection with industry experts at GFN2023 and showcase its newest tobacco harm reduction technology achievements and eco-friendly products. ICCPP firmly believes that actively promoting the relative harm reduction effects of new nicotine products on human body is the right thing to do and also what ICCPP is continuously doing for the sustainable and benign development of the tobacco industry in the future. E-cigarettes were naturally created as an alternative to cigarettes, and ICCPP's researches has continued to confirm that e-cigarettes perform better in terms of harm reduction compared to traditional cigarettes. To be a world-leading and respected health technology company, ICCPP has the responsibility and great willingness to actively promote the public to break the misconceptions about nicotine and new tobacco products and realize the superiority of new tobacco products by committing to scientific research and innovation and speaking with more research and facts.

As we all know, temperature control plays an important role in the effect of new tobacco harm reduction. It is understood that ICCPP will invite its expert in electronic atomization to give an in-depth explanation of the research at GFN2023 and even to expose for the first time its creative and more harm-reducing new e-liquid research results that have been tested and validated for many times. Moreover, considering the public's concern about the environmental pollution caused by the prevalent disposable e-cigarettes, ICCPP will carefully introduce its new double eco-friendly disposable product solutions, providing adult smokers with a eco-friendly, healthier and safer choice.

ICCPP’s Belief: Sustainable Development through Internal and External dedication

The invitation and participation of ICCPP in GFN2023, on behalf of fast- development new tobacco industry is a recognition and support from GFN, one of professional international organizations for ICCPP’s continued technology research and innovation achievements in tobacco harm reduction, as well as a great expectation for its continuous progress and development.

In addition, in the face of the complex and rapidly changing nicotine market and the tightening situation of global regulations and compliance, ICCPP, as a comprehensive health ecology enterprise with the identity of C-sides brands and B-sides manufacturer in the industry, needs to cultivate itself both internally and externally. On one hand, ICCPP should "cultivate internal strength", aiming at harm reduction, green and environmental protection, and with the user-centered philosophy to continue to make achievements in research and technology innovations. On the other hand, we need to be deeply open, actively participate in the external international stage, make open and equal dialogues with international stakeholders, gain a keen insight into international trends to feed the research of technology and product applications, thus seeking good opportunities in challenges for sustainable development.

In the future, ICCPP Group will continue to strengthen its technology research and innovation to provide more feasible and popular cigarette alternatives for adult smokers, and aspire to become a technology pioneer in the e-cigarette industry and an application leader in ecological tobacco harm reduction technology, actively applying technology and product innovation to truly create a better future for users.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Carol Lu
Email: carol@iccpp.com
TEL: 18774838678

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Galderma Intends to Buy Back approximately 2.4 Million Shares in the Context of the Accelerated Bookbuild Offering by EQT, ADIA and Auba27.5.2025 18:46:00 EEST | Press release

Galderma Group AG (SWX:GALD): Ad hoc announcement pursuant to Art. 53 LR Galderma intends to repurchase approximately 2.4 million shares in the context of the accelerated bookbuild offering of Galderma shares by Sunshine SwissCo GmbH (“EQT”), Abu Dhabi Investment Authority (“ADIA”) and Auba Investment Pte. Ltd. (“Auba”) announced today The repurchased shares will be held in treasury and financed by existing liquidity at hand Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that it intends to repurchase approximately 2.4 million Galderma shares in the context of an accelerated bookbuilding offering (“ABO”) of approximately 16.7 million Galderma shares (approximately 7% of Galderma’s share capital) by EQT, ADIA and Auba. Galderma will participate in the ABO at the same price per share which will be determined in the bookbuilding. The repurchased shares will be financed by Galderma’s existing liquidity on hand and will not affect the company’s ability to de

New South Wales Minister for Industry and Trade Visits Novotech Seoul Office to Strengthen Clinical Trial Collaboration27.5.2025 18:44:00 EEST | Press release

Novotech, a globally recognized full-service clinical research organization (CRO) and scientific advisory company trusted by biotech and small- to mid-sized pharmaceutical companies to guide drug development at every phase, was honored to welcome The Hon. Anoulack Chanthivong, New South Wales (NSW) Minister for Industry and Trade, to its Seoul office on May 19. The Minister’s visit highlights a deepening collaboration between South Korea and Australia in the field of clinical research and highlights the strategic importance of cross-border partnerships in advancing global drug development. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250527294947/en/ Novotech, a globally recognized full-service clinical research organization (CRO) and scientific advisory company trusted by biotech and small- to mid-sized pharmaceutical companies to guide drug development at every phase, was honored to welcome The Hon. Anoulack Chanthivong,

LambdaTest Introduces Automation MCP Server to Revolutionize Test Failure Triaging27.5.2025 18:00:00 EEST | Press release

LambdaTest, a unified agentic AI and cloud engineering platform, has announced the launch of its Automation MCP Server, a breakthrough solution designed to simplify and accelerate the process of triaging test failures. By enabling direct integration between AI assistants and LambdaTest’s test execution data, the Automation MCP Server empowers developers and QA engineers to investigate and resolve issues faster, without leaving their integrated development environment (IDE). The Automation MCP Server offers a seamless interface within the IDE, allowing users to access and analyze real-time test data with ease. With intelligent root cause analysis, the MCP server can quickly identify the underlying reasons for test failures and take immediate action to fix the underlying code. This results in fewer debugging cycles and faster release times. The server also enhances automated testing workflows by enabling the generation of new test cases using real execution data. Developers can leverage

The Six Winning Projects of the 12 th Edition of the IBSA Foundation Fellowships have been Awarded and the 2025 Call is Now Open27.5.2025 17:58:00 EEST | Press release

Research means investing in the future. This is the guiding principle behind the IBSA Foundation Fellowships programme, which for over a decade has supported talented researchers under 40 from universities and research institutions around the world. The programme awards grants to promote innovative and potentially groundbreaking projects in lesser-explored scientific fields; a constantly growing success, also confirmed by the 2024 edition, which marked a new record, with 259 applications across five scientific areas. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250522244202/en/ The Award Ceremony of the 12th edition of the IBSA Foundation Fellowship The € 32,000 fellowships were awarded to research projects in five scientific areas: dermatology, endocrinology, fertility/urology, pain medicine/orthopaedics/rheumatology and healthy aging/regenerative medicine. In particular, this latter category has attracted growing interes

Rigaku Completes New Building at Yamanashi Plant27.5.2025 17:00:00 EEST | Press release

Rigaku Corporation, a global solution partner in X-ray analytical technologies and a Group company of Rigaku Holdings Corporation (headquarters: Akishima, Tokyo; President and CEO: Jun Kawakami; hereinafter “Rigaku”) completed an additional manufacturing building (hereinafter “the New Building”) at Yamanashi Plant, Rigaku’s main production facility. The facility was established to serve as the center of Rigaku’s production framework, in anticipation of global business growth and expansion in product demand. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250527974928/en/ Exterior view of the New Building, Yamanashi Plant Doubling of production capacity: a strategic base to support Rigaku’s growth Demand for X-ray analytical solutions has soared in recent years, both in Japan and worldwide. To respond to growing demand, Rigaku implemented this expansion with two key objectives in mind. One objective is to further reinforce the

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye